ACOR News and Press, Acorda Therapeutics Inc. From 12/21/18

First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa Expected to be Available by Prescription in First Quarter 2019 Based on Innovative ARCUS ® Technology Platform for Inhaled Drug ...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h...

Acorda Therapeutics, Inc. (ACOR) Q3 2018 Earnings Conference Call October 31, 2018 8:30 A.M. ET Executives Felicia Vonella - Executive Director-Investor Relations Ron Cohen - Chief Executive Officer Analysts Carmen Augustine - JPMorgan Kelechi Chikere - Jefferies Phil Nad...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q3 earnings Read more ...

Acorda Therapeutics (NASDAQ: ACOR ): Q3 Non-GAAP EPS of $0.17 beats by $0.31 ; GAAP EPS of -$0.29 beats by $0.01 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

AMPYRA ® (dalfampridine) Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million Cash balance for year-end 2018 revised from more than $300 million to more than $400 million INBRIJA™ (levodopa inhalation...

ACOR , ADP , AEE , AIT , ANTM , APO , APTV , ARCC , AUO , BAX , BCOR , BDC , BG , CAMT , CBZ , CDW , CG , CIM , CLH , CLX , CRTO , CVE , DBD , DIN , EGL , EL , EPD , ETR , GM , GNC , GRMN , HCP , HES , HFC , HSC , IART , ICE , ICPT , IGT , K , LFUS ,...

Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca...

Acorda Therapeutics (NASDAQ: ACOR ) is up  8%  premarket on light volume on the heels of its disclosure that the FDA's pre-approval inspections of its Chelsea, MA manufacturing facility and the Inbrija inhaler device maker's facility have been completed with no further action req...